Valerie Fessard

Dr. Valerie Fessard

French Agency for Food, Environmental and Occupational Health and Safety, Laboratoire de Fougères, Unité Toxicologie des Contaminants, 10B rue C. Bourgelat, CEDEX, 35 306 Fougères, France
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
MPMaxi B. Paul
Maxi B. Paul
VSValerie Stock
Valerie Stock
JCJulia Cara-Carmona
Julia Cara-Carmona
ELElisa Lisicki
Elisa Lisicki
SSSofiya Shopova
Sofiya Shopova
LBLinda Böhmert
Linda Böhmert
This review focuses on micro- and nanoplastic particles with the main focus on oral uptake and transport at the intestinal epithelium and potential toxic consequences.

1 June 2008 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
RJRozenn Jossé
Rozenn Jossé
CACaroline Aninat
Caroline Aninat
DGDenise Glaise
Denise Glaise
JDJulie Dumont
Julie Dumont
VFValerie Fessard
Valerie Fessard
AGAndré Guillouzo
André Guillouzo
The human hepatoma HepaRG cells are able to differentiate in vitro into hepatocyte-like cells and to express various liver-specific functions, including the major cytochromes P450. This study was aimed to determine whether differentiated HepaRG cells retained their specific functional capacities for a long time period at confluence. We show that expression of transcripts encoding CYP1A2, 2B6, 3A4, and 2E1, several phase II and antioxidant enzymes, membrane transporters, including organic cation transporter 1 and bile salt export pump, the nuclear receptors constitutive androstane receptor and pregnane X receptor, and aldolase B remained relatively stable for at least the 4-week confluence period tested. Similarly, activities of CYP3A4 and CYP1A2 and their responsiveness to prototypical inducers were well preserved. Aflatoxin B1, a potent hepatotoxicant and carcinogen, induced a dose-dependent and cumulative cytotoxicity. Furthermore, at a concentration as low as 0.1 μM, this mycotoxin caused a decrease in both CYP3A4 activity and intracellular ATP associated with morphological alterations, after 14 days following every 2-day exposure. Moreover, using the comet assay, a dose-dependent DNA damage was observed after a 3-h treatment of differentiated HepaRG cells with 1 to 5 μM aflatoxin B1 in the absence of any cell damage, and this DNA damaging effect was strongly reduced in the presence of ketoconazole, a CYP3A4 inhibitor. These results bring the first demonstration of long-term stable expression of liver-specific markers in HepaRG hepatocyte cultures maintained at confluence and show that these cells represent a suitable in vitro liver cell model for analysis of acute and chronic toxicity as well as genotoxicity of chemicals in human liver.

22 December 2017 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
PLPeter Laux
Peter Laux
JTJutta Tentschert
Jutta Tentschert
CRChristian Riebeling
Christian Riebeling
ABAlbert Braeuning
Albert Braeuning
OCOtto Creutzenberg
Otto Creutzenberg
ALAndreas Luch
Andreas Luch
Development and market introduction of new nanomaterials trigger the need for an adequate risk assessment of such products alongside suitable risk communication measures. Current application of classical and new nanomaterials is analyzed in context of regulatory requirements and standardization for chemicals, food and consumer products. The challenges of nanomaterial characterization as the main bottleneck of risk assessment and regulation are presented. In some areas, e.g., quantification of nanomaterials within complex matrices, the establishment and adaptation of analytical techniques such as laser ablation inductively coupled plasma mass spectrometry and others are potentially suited to meet the requirements. As an example, we here provide an approach for the reliable characterization of human exposure to nanomaterials resulting from food packaging. Furthermore, results of nanomaterial toxicity and ecotoxicity testing are discussed, with concluding key criteria such as solubility and fiber rigidity as important parameters to be considered in material development and regulation. Although an analysis of the public opinion has revealed a distinguished rating depending on the particular field of application, a rather positive perception of nanotechnology could be ascertained for the German public in general. An improvement of material characterization in both toxicological testing as well as end-product control was concluded as being the main obstacle to ensure not only safe use of materials, but also wide acceptance of this and any novel technology in the general public.

7 June 2016 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ACAndrew Collins
Andrew Collins
ABAnnangi Balasubramanyam
Annangi Balasubramanyam
LRLaura Rubio
Laura Rubio
RMRicard Marcos
Ricard Marcos
MDMarco Dorn
Marco Dorn
Maria DusinskaMaria Dusinska
Maria Dusinska
With the growing numbers of nanomaterials (NMs), there is a great demand for rapid and reliable ways of testingNMsafety—preferably usingin vitroapproaches, to avoid the ethical dilemmas associated with animal research. Data are needed for developing intelligent testing strategies for risk assessment ofNMs, based on grouping and read‐across approaches. The adoption of high throughput screening (HTS) and high content analysis (HCA) forNMtoxicity testing allows the testing of numerous materials at different concentrations and on different types of cells, reduces the effect of inter‐experimental variation, and makes substantial savings in time and cost.HTS/HCAapproaches facilitate the classification of key biological indicators ofNM‐cell interactions. Validation ofin vitroHTStests is required, taking account of relevance toin vivoresults.HTS/HCAapproaches are needed to assess dose‐ and time‐dependent toxicity, allowing prediction ofin vivoadverse effects. SeveralHTS/HCAmethods are being validated and applied forNMtesting in theFP7projectNANoREG, including Label‐free cellular screening ofNMuptake, HCA, High throughput flow cytometry, Impedance‐based monitoring, Multiplex analysis of secreted products, and genotoxicity methods—namely High throughput comet assay, High throughputin vitromicronucleus assay, andγH2AXassay. There are several technical challenges withHTS/HCAforNMtesting, as toxicity screening needs to be coupled with characterization ofNMsin exposure medium prior to the test; possible interference ofNMswithHTS/HCAtechniques is another concern. Advantages and challenges ofHTS/HCAapproaches inNMsafety are discussed.WIREs Nanomed Nanobiotechnol2017, 9:e1413. doi: 10.1002/wnan.1413This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

9 November 2009 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
PDF file
EBEmmanuelle Bazin
Emmanuelle Bazin
AMAnnick Mourot
Annick Mourot
AHAndrew R. Humpage
Andrew R. Humpage
VFValerie Fessard
Valerie Fessard

1 March 2015 in Toxicology in Vitro
Verified
Journal Article
Closed access
ATAdeline Tarantini
Adeline Tarantini
RLRachelle Lanceleur
Rachelle Lanceleur
AMAnnick Mourot
Annick Mourot
MLMarie -Thérèse Lavault
Marie -Thérèse Lavault
GCGérald Casterou
Gérald Casterou
VFValerie Fessard
Valerie Fessard